Eli Lilly and Co.'s experimental drug necitumumab, or IMC-11F8, in combination with gemcitabine and cisplatin, met the primary goal of a Phase III trial by improving overall survival in patients with stage 4 squamous nonsmall-cell lung cancer compared with chemotherapy alone. The firm plans to submit the drug for FDA approval next year as a first-line therapy for squamous lung cancer. If approved, necitumumab would be the first biologic therapy for the condition.

Related Summaries